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1. INTRODUCTION 
1.1. Costello syndrome 
Costello syndrome (OMIM 218040; Faciocutaneoskeletal syndrome; FCS syndrome) 
is a rare congenital disorder characterized by postnatal growth deficiency, mental retardation, 
"coarse" face, loose skin of the neck, hands, and feet, cardiomyopathy, and nasal papillomata. 
The first cases were described in 1971 and 1977 [1, 2]. To date, the genetic basis of Costello 
syndrome is unknown. Autosomal dominant inheritence with de novo mutations has been 
suggested by Lurie [3] to explain the usually sporadic occurrence of the syndrome. 
The hypothesis of autosomal recessive inheritance of Costello syndrome was based on 
2 families with affected sibs [4, 5] and 2 consanguineous matings [3, 6]. Lurie [3] reviewed 
20 reported families and found that the 37 sibs of probands were all normal. In 6 families for 
whom pedigrees were not available, 2 affected sib-pairs were bom. Even if there were no 
normal offspring in these latter families, the occurrence of the Costello syndrome in only 2 of 
39 sibs virtually excludes an autosomal recessive inheritance pattern (P = 0.999). Moreover, a 
significant increase of mean paternal age (38.0 years) and paternal-maternal age difference 
(7.36 years) suggests sporadic autosomal dominant mutations as a likely cause. The 2 reported 
cases of affected sibs bom to healthy parents may be explained by germline mosaicism, 
although heterogeneity with a small proportion of recessively inherited cases cannot be 
excluded. In line with this hypothesis, advanced paternal age has been also found in the 
families analyzed by Johnson et al. [7]. The putative male to male transmission of Costello 
syndrome is also consistent with an autosomal dominant inheritance. 
Because of phenotypic overlap between Costello syndrome and Noonan syndrome, 
and because mutations in the PTPN11 gene had been demonstrated in the latter, Tartaglia et 
al. [8] screened a cohort of 27 patients with clinically diagnosed Costello syndrome for 
PTPN11 mutations; they found none. The exclusion of PTPN11 mutations in 
cardiofaciocutaneous syndrome by Ion et al. [9] indicates that these 3 syndromes are distinct. 
A first clue to map the gene was provided by a Costello patient carrying an apparently 
balanced chromosomal translocation t(l;22) (q25;ql 1) [10]. 
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1.2. Oxidative stress in neonates 
Birth itself causes mechanical and oxidative stress for newborns. All infants, regardless 
of gestational age, have shown evidence of oxidative stress during the first few days after 
birth, especially premature infants, who have much lower antioxidant capacity than term 
babies [11, 12]. The switch to aerial breathing, the increased partial O2 concentration and the 
stress caused by birth induces many physiological processes, most notably the neonatal 
adaptation to the greatly changed conditions. 
Part of the adaptation is the rapid degradation of fetal hemoglobin and the oxidation of 
its heme moiety by heme oxygenases (HO), which are contributing factors in the development 
of post parturition hyperbilirubinemia. The released free heme is an aggressive oxidative 
agent which can be directly cytotoxic [13] and it can also become toxic by mediating 
oxidative stress and inflammation [14]. 
1.3. Oxidative stress in hemodialysed patients 
The principal causes of morbidity and mortality in patients with end-stage renal disease 
(ESRD) requiring long-term hemodialysis (HD) are cardiovascular complications [15-17]. 
Even as adolescents these patients have rapidly progressing arterial diseases, arteriosclerosis, 
and atherosclerosis [15-17]. Previous experimental and clinical studies have highlighted the 
role of leukocytes in generating reactive oxygen metabolites as a primary mechanism of 
oxidative stress during each HD session. Additional factors include a decreased antioxidant 
protective capacity of uremic patients long before the initiation of maintenance HD, a status 
of malnutrition and/or inflammation, together with a progressive worsening of the clinical 
condition [17, 18]. C-reactive protein (CRP) levels are elevated in ESRD patients undergoing 
HD and are significantly associated with malnutrition, hypoalbuminemia, and erythropoietin 
resistance [17]. Asymmetric dimethylarginine (ADMA)—an endogenous inhibitor of nitric 
oxide synthase—levels are markedly increased in patients with ESRD as a consequence of 
reduced renal excretion. Both CRP and ADMA are important risk factors for cardiovascular 
disease and mortality in the ESRD population and are associated with increases in the 
incidence and progression of atherosclerotic lesions in carotid arteries. 
Hyperhomocysteinemia has been reported to be an independent risk factor for vascular 
diseases through a mechanism involving oxidative damage [19]. It has been shown that 
patients with ESRD have an impaired antioxidant response and therefore are at an increased 
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risk for inflammation, hemolysis, and arteriosclerosis [18, 20, 21]. HD treatment imposes 
additional oxidative stress due to the bioincompatibility of dialyzer membranes and activation 
of macrophages, as well as the presence of potentially toxic substances in the dialysis water 
supply [21]. 
1.4. Role of heme oxygenases 
Heme oxygenases catalyze the rate-limiting step in heme degradation, resulting in the 
formation of iron, carbon monoxide, and biliverdin, which is subsequently converted to the 
antioxidant bilirubin (Bi) by biliverdin reductase [22] (Fig. 1.). Biliverdin and bilirubin are 
potent antioxidant themselves and play a protective role against further oxidative stress [23-
26]. The transiently enhanced HO-1 mRNA accumulation is a sensitive marker of oxidative 
stress [27] and the induced HO-1 plays a cytoprotective role in oxidative stress and heme-
mediated injury [28-30], 
Fcrroxit 
Biliverdin 
reductase 
Heme Biliverdin ^ Bilirubin 
C O 
Fig. 1. The catabolic degradation of heme by Heme oxygenases. 
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1.4.1. Mapping 
Two functional HO isoforms are known HMOX1 (GenelD: 3162, OMIM: 141250) and 
HMOX2 (OMIM: 141251) in humans: HMOX2 is the constitutional form, while HMOX1 is 
the form transcriptionally inducible by a variety of agents, such as heme, oxidants, 
inflammatory cytokines, UV irradiation, heavy metals and arsenite [31, 32]. Using the 
polymerase chain reaction for analysis of human/rodent somatic cell hybrids, Kutty et al. [33] 
assigned the HMOX2 gene to chromosome 16. They regionalized the assignment to 16pl3.3 
by FISH. Using polymerase chain reaction to study a mapping panel of human/rodent somatic 
cell hybrids, Kutty et al. [33] localized HMOX1 to chromosome 22. By fluorescence in situ 
hybridization (FISH), they refined the assignment to 22ql2. Seroussi et al. [34] characterized 
a 190.3-kb contig in human 22ql3.1 and identified the HMG2L1 (High Mobility Group 
Protein 2-Like 1) and TOM1 (Target of MYB1) genes, as well as the previously identified 
HMOX1 and MCM5 (Mini Chromosome Maintenance homolog 5) genes. The order of these 
genes is cen~HMG2Ll~TOMl~HMOXl~MCM5~tel. All are oriented in a 5-prime to 3-
prime direction from centromere to telomere. 
1.4.2. Animal model 
Growth retardation, anemia, iron deposition, and vulnerability to stressful injury are all 
characteristics observed in mice in whom the heme oxygenase-1 gene has been knocked out 
[35]. Wagener et al. [36] investigated the involvement of heme and its degrading enzyme 
heme oxygenase in the inflammatory process during wound healing, studying Wistar rats. 
They observed that heme directly accumulates at the edges of a wound and that this coincided 
with an increased adhesion molecule expression and the recruitment of leukocytes. 
Intradermal administration of heme 24 hours before injury resulted in heme-induced influx of 
both macrophages and granulocytes. Heme-oxygenase 1 was significantly expressed in the 
epithelium of both the mucosa and the skin of animals without wounds. On inflammation, its 
expression increased, particularly in infiltrating cells during the resolution phase of 
inflammation. They interpreted their results as indicating that local release of heme may be a 
physiologic trigger to start inflammatory processes, whereas heme oxygenase 1 antagonizes 
inflammation by attenuating adhesive interactions and cellular infiltration. The basal level of 
heme oxygenase expression in the skin may serve as a first protective environment against 
acute oxidative and inflammatory insults. 
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1.4.3. Clinical features 
Yachie et al. [37] reported the first human case of heme oxygenase-1 deficiency. 
Sequence analysis of the patient's HMOX1 gene showed complete loss of exon 2 of the 
maternal allele and a 2-nucleotide deletion in exon 3 of the paternal allele; a normal HMOX1 
gene contains 5 exons. The patient was 26 months old when he was first brought for medical 
care because of recurrent fever and generalized erythematous rash. Growth retardation was 
apparent and marked hepatomegaly was noted, but the spleen was not palpable. Asplenia was 
confirmed by abdominal ultrasonography and isotope image scanning. Hematuria and 
proteinuria were consistently present. At 6 years of age, the boy had severe growth 
retardation. Persistent hemolytic anemia was characterized by marked erythrocyte 
fragmentation and intravascular hemolysis, with paradoxical increase of serum haptoglobin 
and low bilirubin. They described severe persistent endothelial damage at the patient. Electron 
microscopy of renal glomeruli revealed detachment of endothelium, with subendothelial 
deposition of an unidentified material. Iron deposition was noted in renal and hepatic tissue. 
Immunohistochemistry of hepatic tissue and immunoblotting of a lymphoblastoid cell line 
revealed complete absence of heme oxygenase-1 production. A lymphoblastoid cell line 
derived from the patient was extremely sensitive to hemin-induced cell injury. 
1.4.4. Role of HOs during oxidative stress 
Much controversy exists regarding the predominant effect of HOs in the setting of 
oxidative injury (Fig 2.). This is rooted in the further biochemistry of heme breakdown 
products [38]. HOs may have a pro-oxidant effect, as the iron released from heme (in the 
setting of low ferritin availability) may react with hydrogen peroxide via the Fenton reaction 
to form hydroxyl radicals [39-41]. On the other hand producing biliverdin and its metabolite 
bilirubin, however, HOs may act with an antioxidant effect [42, 43], because bilirubin is a 
potent antioxidant [23-26]. The effect of HOs on oxidative cell injury may vary considerably 
with cell type, level of expression, and chemical properties of the oxidant [39, 44-46]. 
Furthermore, HOs convert a lipid-soluble oxidant (heme) into iron, which can be sequestered 
with ferritin, when available. This protects the cell from lipid peroxidation that would 
otherwise occur, particularly considering the affinity of heme for the hydrophobic cell 
membrane interior [47]. 
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Fig. 2. The breakdown of heme. Heme derived from hemoglobin in senescent erythrocytes, other 
heme proteins, or newly synthesized is degraded by HO into biliverdin, CO, and iron. Biliverdin gets 
converted into the anti-oxidant bilirubin by biliverdin reductase. Ferric iron (Fe3+) is directly 
sequestered by ferritin. CO can interact with heme proteins (e.g., guanylyl cyclase) and alter their 
activity. Heme and its breakdown products possess various physiological properties but are also 
potentially toxic. 
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1.3. The aim of the study 
1. To date, the genetic basis of Costello syndrome is unknown therefore our aim was to 
refine the break point regions of a Costello syndrome patient with an apparently 
balanced chromosomal translocation t(l;22) (q25;qll) at the molecular level by 
FISH. 
2. There was a need to establish a scaleable and sensitive method to measure the HO-1 
expression because of the limited amount of samples available from premature. 
3. Although HO-1 induction may be a general and adaptive response to oxidant stress, 
the inducibility of this enzyme in the early postnatal period in human newborns had 
not been studied yet. We hypothesized that enzymatic immaturity of HO-1 or its 
regulation system could play a role in the early transitory adaptation disturbances of 
premature neonates. Therefore our aim was to investigate the HO-1 expression in 
mature and premature neonates during the fist week after birth to find out if the 
enzyme is inducible and whether there are any differences between the two groups. 
4. The changes in Hb metabolism in uremic patients are the major cause of HD-
mediated endothelial injury. Therefore our aim was to follow the effects of single 
HD sessions on the plasma hemoglobin and bilirubin as indicators of hemolysis, the 
ferroxidase activity, the erythrocyte-derived reduced and oxidized glutathione levels 
and HO-1 mRNA expression as oxidative stress markers, and the homocysteine 
levels as and independent risk factor. 
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2. METHODS AND PATIENTS 
2.1. Methods used in the positional cloning experiments 
2.1.1. Cultivation of Yeast artificial chromosome (YAC), P1-artificial 
chromosome (PAC), Bacterial artificial chromosome (BAC) and cosmid clones 
The selected yeast strains containing our YAC inserts were spread and incubated on 
plate for 2-3 days on 30°C on DOB medium with CSM -TRP -URA (0.7 gr/1) according to 
Burke et al. [48]. Single colonies were innoculated in 2ml of DOB A (43.7 gr/1) medium and 
incubated for 1 day on 30°C on a shaker. The yeast strains were transferred in 50ml DOBA 
medium (43.7 gr/1) and incubted for 2 days 30°C on a shaker. PAC, BAC, and cosmid cultures 
were grown in 2ml of LB medium in the presence of the appropriate antibiotic at 30°C until 
an OD6OO of 0.6 0.8 was reached. 
2.1.2. Isolation of the DNA insert from YAC, PAC, BAC and cosmid clones 
The protocol to separate yeast DNA from the culture was based on that of Philippsen 
et al. [49]. The obtained yeast chromosomes were run on a 1.2% low-melting-point agarose 
gel by pulse field electrophoresis (initial time 70 s, final time 90 s, 6 V/cm, for 24 h). Gels 
were stained for 15 minutes with ethidium bromide and subjected to UV light for 
visualization of the DNA. The extra bands containing the YAC insert were cut out by scalpel. 
The DNA was isolated from the low-melting-point agarose and purified. For PAC, BAC and 
cosmid clones DNA was prepared from 2 ml of culture using a standard alkali miniprep 
protocol [50]. 
2.1.3. Fluorescence in situ hybridization (FISH) experiments 
The chromosomes and nuclei spread was prepared from metaphase stopped fibroblast 
culture of the patient as described in Kutsche et al. [51]. The probes were nick translated with 
biotin-dUTP (Nick Translation System, Gibco BRL, Gaithersburg, MD). The YAC, PAC, 
BAC, cosmid probes were labeled by fluorescein isothiocyanate (FITC). Additionally a TEL 
lq DNA probe labeled with Texas red was used to visualize chromosome 1. The 
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chromosomes were counterstained with 4',6-Diamidino-2-phenylindole (DAPI). 
2.2. Methods used in the gene expression experiments 
2.2.1. RNA extraction and competitive reverse transcriptase (cRT)-PCR 
experiments 
The Human DNA sequence from clone CTA-286B10 on chromosome 22 (Nucleotide 
accession no: Z82244, GenBank: 3191962) was used to design the primers for the 
experiments. The primers were designed by the OLIGO software package. Since the clone 
contained the genomic sequence of HMOX1 thus we could design the primers to span exon 
boundaries to avoid binding of primers at DNA level (Fig. 3A). The amplicon and primer 
binding sites were checked by RepeatMasker and BLAST-ed to database 'nr' to avoid 
designing primers into repeat regions or other conservative protein motifs. 
The mRNA was extracted from 1 ml (lOOpl in case of neonates) of venous blood with 
the mRNA Isolation Kit for Blood/Bone Marrow (Roche Diagnostics, Mannheim, Germany). 
Competitive reverse transcriptase PCR was used to identify the expression of heme 
oxygenase-1 gene. The competitor RNA was created by in vitro mutagenesis from HMOX1 
cDNA and transcription with T3 RNA polymerase (Fermentas AB, Vilnius, Lithuania) 
according to Waha et al. [52]. The primers to generate the competitor were as follows: 
HMOX1-T3 5' AAT TAA CCC TCA CTA AAG GGA GAC GTT TCT GCT 
CAA CAT CCA GCT C 3' 
HMOXl-mut 5' CCT GGG AGC GGG TGT TGA GTG GGG GGC AGA ATC 
TTG CAC TTT G 3' 
To avoid error due to RNA degradation the competitor RNA fragment was diluted and 
aliquoted into Eppendorf tubes (3 pi / tube) and stored on minus 70°C till usage. For each 
measurement a new tube of competitor RNA was thawed and used with freshly separated 
HMOX1 mRNA for the RT step. 
First-strand cDNA was generated by using the RevertAid First Strand cDNA 
Synthesis Kit (Fermentas AB) with the specific primer of HMOX1-R. To avoid pipetting 
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errors the method described in the cDNA synthesis protocol was altered (Table 1.). We 
dissolved HMOX1 mRNA in 5 times more RNase free water and we used an extra 6 times 
dilution step at the preparation of competitor RNA dilutions. 
Table 1. Altered cDNA synthesis mix 
original protocol altered protocol 
HMOX1 mRNA 1 pi 5 pi (5x diluted) 
Competitor mRNA 1 pi 6 pi (6x diluted) 
lOOnMHMOXl-R 1 pi l p l 
RNase free H20 9 pi -
lOmMdNTPs 2 pi 2 pi 
RNase inhibitor 1 pi l p l 
5x synthesis buffer 4 pi 4 pi 
reverse transcriptase 1 pi l p l 
For practical reasons (amount of sample available, expected range of HMOX1 mRNA 
induction) we used a four step (3x) dilution of competitor RNA. 
The PCR amplification was carried out with the following program: initial denaturation 
at 94°C for 5 min, followed by 25 cycles of denaturation at 94°C for 20 s, annealing at 61°C 
for 30 s and extension at 72°C for 20 s, followed by a final extension at 72°C for 10 min. The 
primers were as follows: 
HMOX1-F 5' CGT TTC TGC TCA ACA TCC AGC TC 3' 
HMOX1-R 5' CCT GGG AGC GGG TGT TGA GTG 3' 
The amplified cDNAs were examined on 6% polyacrylamide gels and stained with 
ethidium bromide. The target HMOX1 band was calculated by the ratio to the competitor by 
densitometry (Alphalmager, AlphaEase 5.5) (Fig. 3B). HMOX1 mRNA concentrations were 
expressed with reference to the white blood cell count; since we did not calculate the copy 
number of our control RNA, these are relative values (we used the same dilutions of control 
RNA). Control RNA and mRNA were handled together in the same tubes, their relative ratio 
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therefore remaining the same throughout the whole process. 
B 
exon4 exon 5 
HM0X1-mut 
before HD after HD 48h after HD 
HMOXt-F HMOX1-R 
i 1 i 
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Fig. 3A. Part of HMOX1 CDS from exon 3 to 5, HMOX1-T3 and HMOX1-mut were used to create a 
polymerase chain reaction (PCR) product from which we transcribed our control RNA, the sequence of 
which differs from that of wild-type HMOX1 mRNA in only a 20-bp deletion. The mRNA and control 
RNA were reverse transcribed and consecutively amplified by the same primers HMOX1-F and 
HMOX1-R. 
B HMOX1 mRNA expression of a patient with oxidative hemolysis before, after and 48 h following 
hemodialysis (HD). A four-step (3x) dilution of control RNA was reverse transcribed with equal 
amounts of mRNA and amplified by the same PCR primers. The arrows show where the mRNA 
concentration is equal to the control RNA concentration 
2.2.2. Biochemical methods 
Blood Hb concentration was measured with an OSM 3 Hemoximeter (Radiometer, 
Copenhagen, Denmark). For the assay of plasma Hb and its oxidized metabolites, metHb and 
hemichrome, heparinized plasma samples were diluted 1:40 (v/v) with 5 mmol/L PBS, pH 
7.4, and measured spectrophotometrically at different wavelengths according to the method of 
Winterbourn [18]. Plasma concentrations of the unbound Bi were estimated by 
spectrophotmetric method of Jacobsen and Wennberg [53]. The total ferroxidase (FOX) 
activity and the ceruloplasmin ferroxidase activity in the plasma were measured with 
conalbumin according to Johnson et al. [54]. Homocysteine concentrations were measured by 
HPLC according to Feussner et al. [55]. 
Reduced (GSH) and oxidized glutathione (GSSG) concentrations were measured 
separately in the whole blood by a combination of previously accepted standard methods [56], 
and were expressed with reference to Hb determined by the cyanmethemoglobin method. 
All biochemical measurements were performed in duplicate. The precision of the 
methods was followed by estimating the coefficients of variation (CV). The intra- and 
interassay CVs for all the biochemical analyses were between 3.0 and 6.0%. 
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2.3. Patients 
We analyzed the Costello syndrome patient (a Hungarian girl) described by Czeizel and 
Timar [10]. We had fibroblast cells which were cultured and used for the FISH experiments. 
We analyzed the HO-1 mRNA expression in three groups of patients. The mature 
neonate patient group was obtained from the Department of Gynecology, the premature 
neonate group was obtained from the perinatal intensive center of Department of Pediatrics. 
The young adult hemodialysed patients were obtained from the hemodialysis center of the 
Department of Pediatric. 
2.3.1. Characterization of the Costello syndrome patient 
The Hungarian girl with Costello syndrome had an apparently balanced translocation: 
46,XX t(l;22)(q25;ql 1). The karyogram of the patient is shown on Fig. 4. The patient showed 
excessive generalized skin, more pronounced in the palms, 'wash woman's hands,' and soles, 
with elastolysis confirmed by histologic examination. The long tubular bones were 
osteoporotic. Spina bifida occulta was demonstrated in L5 and SI. Mental retardation was 
mild. She had a particularly sociable and humorous personality. 
Fig. 4. Chromosome 1;22 translocation in the patient. GTG-banded pairs of the patient with an 
apparently balanced and reciprocal translocation [t(1 ;22) (q25;q12)] are shown and ideograms of wild-
type chromosomes 1 and 22. 
m * 
H * 
(der)1 1 (der)22 22 
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2.3.2. Characteristic of mature and premature neonates 
We analyzed 21 mature (gestational time are 37-40 weeks, birth weight: median 3305g; 
quartiles 3060g, 3770g) and 20 premature neonates (gestational time are 26-36 weeks, birth 
weight: median 1860g; quartiles 1450g, 2230g) with transient neonatal adaptation difficulties. 
We excluded babies with respiratory distress, sepsis, positive bacteriology or any serious 
complication (intracerebral hemorrhage, necrotizing enterocolitis, pneumonia, pneumothorax, 
and any congenital heart disease). None of the examined patients were on mechanical 
ventilation (>24h) and none of them had blood transfusion during the investigation period. 
The indication of phototeraphy was according to the practice written in "Care of the 
High-Risk Neonate" [57]. The patients requiring phototherapy were on intermittent therapy 
(425-475 nm light/normal light in 4 hour intervals). None of the mature neonates had to be 
supplied with extra 02. Ten premature neonates with a transitory adaptational disturbance 
were on extra 0 2 (<24 h). Indication of extra oxygen support was determined by Pa02 values 
(the Pa02 levels were kept in the range of 50-70 mmHg in term newborns, and 40-60 mmHg 
in prematures with less than 1500 g birth weight). The Fi02 values in these patients were 0.4 
(quartiles 0.3,0.6). 
Whole blood samples were collected in EDTA microtainer tubes (approx. 200 pi per 
sample) during the first week following birth. For mRNA analysis lOOpl were pipetted out 
immediately into 1ml RNA stabilization reagent. Quantitative blood count was performed on 
an ABX Micros 60 hematological automat. 
We obtained blood samples from mature newborns in parallel with the routine serum 
bilirubin assay, usually 2-3 samples from each babies before they left the obstetrical ward. We 
obtained blood samples from premature newborns each day following birth (7 samples from 
each babies). 
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2.3.3. Characteristic of HD patients 
17 HD patients dialyzed in our dialysis unit were included in the study. The duration of 
HD treatment in these 17 patients was 38 months (median, quartiles: 16; 102). The patients 
were grouped according to the duration spent in the dialysis program: short-term HD patients 
(n=7, median 19 months, quartiles: 9, 29) and long-term HD patients (n=10, median 97 
months, quartiles: 53, 150). Age, sex, weight and height distribution of the two groups are 
displayed in Table 2. As controls for the biochemical data, age- and sex-matched healthy 
young adult patients were selected from among subjects before undergoing orthopedic surgery 
(n=20). 
Table 2. Demographic characteristics of uremic patients on HD (means ± SD) 
Short-term HD (n=7) Long-term HD (n=10) 
Demographic characteristic of patients 
Age (y) 27.8 ±4 .8 25.1 ±4 .4 
Sex (M/F) 4/3 5/5 
Weight (kg) 53.7 ± 16.2 58.1 ± 18.1 
Height (cm) 159.6 ± 15.2 164.71 ±37.1 
The distribution of the original nephrological diagnosis in the ESRD group was as 
follows: chronic pyelonephritis with reflux nephropathy 7, interstitial nephritis 3, 
membranoproliferative glomerulonephritis 4, focal segmental glomerulosclerosis 2, and 
rapidly progressive glomerulonephritis 1. All these patients had been on antihypertensive 
therapy with a combination of angiotensin-converting enzyme inhibitor and calcium channel 
blocker, and had received 4-h bicarbonate HD 3 times a week with a hemophan single-use 
dialyzer. The blood flow rate was 200 ml/min and the dialyzate flow rate was 500 ml/min. 
During HD, Na-heparin was used as an anticoagulant, in an initial dose of 500 IU, followed 
by continuous infusion at a rate of 1000 IU/h. Erythropoietin treatment was started depending 
on hematocrit and hemoglobin status of uremic patients even before the entry to the HD 
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program. Erythropoietin was given in the range of 30-70 IU/kg/dose post HD after the 
collection of blood samples. We used the formula Kt/V for the evaluation of dialysis 
efficiency; the target value was >1.1. 
Blood samples were collected before, immediately after and 48 h following HD. For the 
analysis of biochemical parameters, 1 ml of anticoagulated (with EDTA and heparin) blood 
was collected. For mRNA separation 1 ml of native blood was collected and stabilized in 
RNA/DNA Stabilization Reagent for Blood/Bone Marrow (Roche Diagnostics GmbH, 
Germany). 
2.4. Statistical analysis 
Clinical data on the patients are reported as means ± standard deviations (x ± SD), while 
results of biochemical analyses are shown in figures as means ± standard errors (x ± SEM). 
Statistical analyses included both parametric (variance analysis, Tukey test and Student's t-
test, unpaired t-test) and non-parametric tests (Wilcoxon rank test). When the extent of 
variance between pairs of groups differed significantly from each other (p < 0.05 in the F-
test), we used the Welch test (d probe) instead of the t test to compare the mean values. 
Correlations between parameters were characterized by calculation of the linear regression 
and correlation coefficients. The level of significance for all tests was taken as 0.05. 
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3. RESULTS 
3.1. FISH analysis of the break point regions of the Costello syndrome 
patient 
We have re-analyzed the chromosomes of this translocation patient by high-resolution 
banding (450- to 550-band level) that confirmed the breakpoint on chromosome lq25, and 
refined that on chromosome 22 to ql2 (Fig. 4.). In order to delineate and define the breakpoint 
regions at the molecular level, FISH analysis was done by YAC, PAC, BAC, and cosmid 
clones from the corresponding chromosomal regions (for methodological details, see Kutsche 
et al. [2000]). For the chromosome lq25 breakpoint, the YAC clone, 786G11 (530 kb), 
positive for microsatellite marker D1S2659, was found to hybridize proximal to the 
breakpoint, whereas two YACs, 807D10 (1,790 kb), positive for marker D1S2640, and clone 
949G05 (1,260 kb), positive for marker D1S222, hybridized distal to the breakpoint (data not 
shown). Based on this data, we selected YAC clone 790F06 (1,390 kb), positive for 
microsatellite marker D1S3424 that, indeed, hybridized to both rearranged chromosomes 1 
and 22 (and to wild-type chromosome 1), confirming the position of the breakpoint in lq25 
(data not shown). For further analysis, three additional YACs from the putative breakpoint 
region were tested by FISH. YAC clone 745G01 (570 kb), positive for D1S3424 and SO ATI, 
hybridized distal to the breakpoint, whereas YACs 897A04 (650 kb), positive for D1S2425 
and D1S2078, and 896A03 (1,130 kb), positive only for D1S2425, hybridized proximal to the 
breakpoint (Fig. 5A). Thus, it seems that YAC 790F06 spans the breakpoint on chromosome 
lq25 mapping it between markers D1S2078 and SOAT1 (Fig. 5A). Subsequently, 43 PAC 
clones were isolated and 14 placed in order to form a partial contig using microsatellite and 
end-sequence STS markers derived from selected PAC clones (Fig. 5B). Of the ramdomly 
selected PACs analyzed in FISH experiments, 10 clones hybridized proximal, and three 
clones distal to the lq25 breakpoint, whereas PAC K1443 was spanning it (Fig. 6, data not 
shown). BlastN analysis of end-sequences generated from K1443 has revealed that one end 
corresponds to position 1628097 in the genomic sequence of contig NT 026949 and the other 
one to position 1747898, giving an insert of 109801 bp. BLAST searches with this 109 kb 
sequence revealed homology to three different EST clusters (UniGene data set Hs. 102398, 
Hs.74104, and Hs.5415) suggesting that at least one gene is located on the breakpoint 
spanning PAC clone on chromosome 1. 
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Fig. 5. Characterization of the translocation breakpoint in 1q25. A: Delineated breakpoint region and 
position of four YACs on chromosome 1q25. The upper line represents a region from 1q25 from 
centromere to telomere that is not drawn to scale. Microsatellite markers are indicated by vertical bars. 
YAC inserts are shown by black lines. Data of FISH analysis with each of the YAC clones are 
indicated on the right. B: Partial PAC contig in 1q25. PAC clones are represented by black lines. 
Microsatellite markers are indicated by vertical bars, and STS end-markers by filled circles. PAC clone 
K1443 (framed) is spanning the breakpoint in FISH experiments. PAC clone mapping proximal to the 
breakpoint are on the left, whereas those located distal to the breakpoint are grouped on the right. 
The breakpoint on chromosome 22 was originally localized by conventional cytogenetic 
analysis and assigned to ql 1 [10]. Since reinvestigation by high-resolution banding suggested 
that the breakpoint was in q l2 (Fig. 4), we performed FISH experiments by YAC clones from 
22ql l -q l2 . 
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FIG 6. FISH with PAC clone K1443 hybridized to lymphocyte metaphase spreads of the patient. The 
probe is labeled by FITC (green). PAC K1443 produces a signal on the wild-type chromosome 1 (q25), 
as well as on der(1) and der(22), indicating that this clone is spanning the breakpoint. A TEL 1q DNA 
probe labeled by Texas red (red) was used to identify the telomere of the long arm of chromosome 1. 
Chromosomes are counterstained with DAPI. 
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Three YACs, 848D02, 891F12, and 742B05, hybridized on several chromosomes, 
indicating that these clones were chimeric (data not shown). Two clones, 765E02 (500 kb), 
and 881H10 (650 kb) hybridized proximal to the breakpoint (Fig. 7A) suggesting that the 
breakpoint region is more telomeric. Similarly, seven additional YAC clones, cytogenetically 
assigned to 22ql 1.2 to ql3.1, hybridized proximal to the breakpoint (Fig. 7A). In contrast, 
two YACs, 803D03 and 924C02, mapped to the end of 22ql3.1 and the beginning of ql3.2, 
hybridized distal to the breakpoint (Fig. 7A). 
q11.1 q11.2 q12.1 q12.2 
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765E02 881H10 938F09 744F06 
846D07 744E01 
q13.1 q13.2 
804G07 851F06 
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B 
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924C02 
CTA-150C2 RP4-742C19 CTA-234D04 
Fig. 7. Characterization of the translocation breakpoint in 22q11-q13. A: The upper line represents a 
region of 22q11 to q13.2 in centromere to telomere orientation that is not drawn to scale. YAC inserts 
are shown by black lines. YAC clones hybridizing proximal to the breakpoint are on the left, whereas 
those hybridizing distal to the breakpoint (underlined) are grouped on the right. B: In the insert, BAC, 
PAC, and cosmid clones analyzed in FISH experiments are shown. Black lines represent sequenced 
regions of these clones. The three PAC/BAC clones on the left hybridized proximal, the two on the 
right (underlined) distal to the breakpoint, whereas cosmid LL22NC03-10C3 (framed) spanned it. 
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Fig 8. FISH with cosmid clone 10C3 hybridized to lymphocyte metaphase spreads of the patient. The 
probe is labeled by FITC (green). Cosmid 10C3 produces a signal on the wild-type chromosome 22 
(q13), as well as on der(1) and der(22), indicating that this clone is spanning the breakpoint. A TEL 1q 
DNA probe labeled by Texas red (red) was used to identifiy the end of the long arm of chromosome 1. 
Chromosomes are counterstained with DAPI. 
Based on this data, FISH analysis refined the cytogenetic breakpoint from 22qll to 
22ql3.1. No YAC clone was found located in the putative breakpoint region. Instead, 
numerous PAC, BAC, and cosmid clones have been used for further FISH experiments. Of 
these, three PAC/BAC clones, CTA-150C02, RP3-494G10, and RP4- 742C19, hybridized 
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proximal and two, CTA-234D04 and RP3-333H23, distal to the breakpoint, whereas cosmid 
LL22NC03-10C3 spanned the breakpoint (Fig. 7B, Fig. 8, data not shown). Analysis of the 
DNA sequence of chromosome 22 deposited in the database (NT_011520) revealed that the 
gene encoding the platelet-derived growth factor beta (PDGFB) is located on the insert of the 
cosmid. 
3.2. Established a sensitive cRT-PCR method 
For the synthesis of the competitor fragment we separated mRNA from the blood of a 
healthy person. This mRNA was reverse transcribed by the specific HMOX1-R primer and 
amplified by PCR with the primers HMOX1-F and HMOX1-R. The size of product was 
verified by gel electrophoresis. This cDNA fragment was then used for PCR based the in vitro 
mutagenesis to create a 20 base pair internal deletion and to add a T3 RNA polymerase 
binding site. We verified the cDNA fragment we used to transcribe the competitive RNA 
fragment with restriction enzyme digestion (Ava II). By electrophoresis we proved that we 
got a specific product from HO-1 mRNA which contains the 20 base pair deletion (Fig. 9). 
The measured sizes of products were in correspondence with the expected undigested and 
digested sizes. 
I - undigested 
II - Avail cleaved 
Fig 9. Avail digestion of cDNA fragment 
used to transcribe the competitor RNA. 
The DNA was run on 8% Polyacrylamide 
gel, and stained with ethidium bromide. 
Fragment sizes were analysed by 
Alphalmager AlphaEase 5.5 
Furthermore we also confirmed that HMOX1-F and HMOX1-R primer pair which were 
designed on exon boundaries does not amplifies unspecific products. We got no unspecific 
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amplicon when genomic DNA was used as template and proved that our primers bound only 
to cDNA reverse transcribed from HMOX1 mRNA. The expression range of HO-1 in 
neonates and uremic patients and the corresponding competitor RNA fragment dilutions were 
determined by analyzing 3-3 samples in a pilot study before our experiments. 
3.3. HO-1 expression in mature and premature neonates 
The hemoglobin (Hb), mean corpuscular volume (MCV), WBC, and platelet count 
(PLT) for the mature and premature newborns were in the normal ranges (Table 3) and their 
changes during the first week excluded the presence of severe anemia, sepsis or inflammation. 
Table 3. Blood count parameters of mature and premature neonates (x ± SD) 
Mature neonates 
n = 21 
Premature neonates 
n = 20 
day 1 day 3 day 5 day 1 day 3 day 5 
Hb (g/1) 159.6±19.6 155.4±23.1 156.6±29.8 184.8±16.0"* 187.0±18.5"* 172.7±18.8"' 
MCV (fl) 110.7±2.9 110.1±4.7 108.4±4.5 109.1±3.8 108.2±3.6 106.2±4.3 
PLT 
(109/1) 
187.5±84.1 198.7±79.3 243.1± 112.6 233.3±67.4 248.7±56.7"* 280.2±96.6*" 
WBC 
(109/1) 
14.75±4.80 9.91±4.01 10.1±4.30 19.3±2.56" 10.83±1.77 10.10±2.23 
t test: P<0.001 ; P<0.005 healthy premature vs. mature neonates 
The relative HO-1 mRNA levels of the mature and premature neonates are shown in 
Fig. 10. The levels and inducibility of HO-1 in the two groups proved similar. HO-1 
expression was induced on days 2 and 3. Later, the HO-1 mRNA levels decreased and 
dropped below the day 1 value by the end of the first week. 
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Fig. 10. Relative HO-1 mRNA levels during the first week after birth in healthy mature and premature 
neonates. Unpaired f test: P<0.005 day 3 vs. day 1; *** P<0.001 last day sample vs. day 3. 
The serum bilirubin levels of the mature and premature neonates are shown in Fig. 1], 
These levels increased significantly after birth in both groups, and were the highest on day 5 
after birth. 
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Fig. 11. Bilirubin levels during the first week after birth in healthy mature and premature neonates. 
Unpaired t test: " P<0.005 day 5 vs. day 1. 
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3.4. HO-1 expression in young hemodialysed uremic patients 
Blood and serum values of controls and hemodialysed patients are displayed in Table 4. 
Both the GSSG concentration and the glutathione redox ratio (GSSG/GSH) were significantly 
higher in the HD patients than in the controls (Table 4). The FOX activity in the HD patients 
(0.89±0.03 before HD) was significantly (P<0.01) higher than that in the controls (0.59±0.01) 
(Table 4). 
Table 4. Concentrations of some biochemical parameters in the whole blood and 
in the plasma of the study population (means ± SEM) 
Controls 
(n=20) 
HD patients 
(n=17) 
before HD Immediately 
after HD 
48 h after HD 
Whole blood values 
Reduced glutathione (GSH) 
(pmol/g Hb) 
7.36 ±0.20 7.46 ± 0.28 7.69 ± 0.28 7.72 ± 0.30 
Oxidized glutathione (GSSG) 
(nmol/g Hb) 
11.5 ±0.56 14.21 ± 1.5+ 13.42 ±2.35 12.85 ±1.65 
Glutathione redox ratio 
(GSSG/GSH) 
0.15 ±0.01 0.19 ±0.02"^ 0.17 ±0.03 0.17 ±0.02 
Plasma values 
Hemoglobin metabolites 
(oxyHb+metHb+ 
hemichrome) (pmol/L) 
10.4 ±0.71 9.54 ± 1.14 11.66 ± 1.23' 10.39 ±0.91## 
Bilirubin (pmol/L) 12.4 ±0.94 12.35 ±1.39 17.01 ± 1.72" 11.81±0.85### 
FOX (IU/L) 0.59 ±0.01 0.89±0.03++ 0.96 ± 0.04' 0.88 ± 0.04## 
Homocysteine (pmol/L) 12.4 ±1.16 35.1 ± 4.41+++ 25.9 ±3.03" 33.7±3.63# 
Tukey test * P<0.05; ** P<0.01 before vs. immediately after HD; # P<0.05; ## P<0.01; ### P<0.001 
immediately after HD vs. 48 h after HD 
t-test+ P<0.05;++ P<0.01;+++ P<0.001 controls vs. dialyzed patients before HD. 
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The plasma Hb (9.54±1.14 before and 11.66±1.23 after HD, P<0.05), Bi (12.35±1.39 
before and 17.01±1.72 after HD, P<0.01), and FOX (0.89±0.03 before and 0.96±0.04 after 
HD, P<0.05) levels increased significantly during HD, but had reverted to the original values 
by 48 h after HD (Table 4). During HD the homocysteine levels (35.1±4.41 before and 
25.9±3.03 after HD, P<0.01) decreased significantly, but these levels in our patients were still 
significantly higher than in healthy controls (12.4±1.16, P<0.001) (Table 4). We did not find 
any significant HD-induced changes in the GSH and GSSG concentrations of HD patients 
either immediately or 48h later (Table 4). 
Table 5. Comparison of some biochemical parameters in the whole blood and 
in the plasma of short-t erm and long-term HD patients (means±SEM) 
Before HD Immediately after HD 
Short-term 
(n=7) 
Long-term 
(n=10) 
Short-term 
(n=7) 
Long-term 
(n=10) 
Whole blood values 
Reduced glutathione (GSH) 
(pmol/g Hb) 
7.76 ±0.43 7.24 ± 0.38 7.90 ±0.44 7.54 ± 0.39 
Oxidized glutathione (GSSG) 
(nmol/g Hb) 
14.7 ± 3.38 14.0 ±1.05 16.1 ±5.19 11.2 ±1.44 
Glutathione redox ratio 
(GSSG/GSH) 
0.18 ±0.04 0.20 ± 0.02 0.19 ±0.06 0.15 ±0.02 
Plasma values 
Hemoglobin metabolites 
(pmol/L) 
(oxyHb+metHb+hemichrome) 
8.49 ±1.76 10.2 ± 1.53 9.04 ±1.45 13.4 ± 1.65 
Bilirubin (pmol/L) 10.7 ±1.17 13.4 ±2.21 13.4 ±1.25 19.5 ±2.56' 
Ceruloplasmin ferroxidase 
(IU/L) 
0.89 ±0.04 0.88 ± 0.04 0.96 ± 0.05 0.96 ±0.06 
Homocysteine (pmol/L) 29.3 ± 6.88 39.5 ±11.0 20.2 ± 4.74' 30.3 ± 8.50' 
t-test * P<0.05 before HD vs. immediately after HD 
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The biochemical parameters in the short-term and long-term HD patients before and 
after HD are presented in Table 5. Bi levels were significantly higher (p<0.05) immediately 
after HD in long-term HD patients than that of short-term HD patients. Homocystein levels of 
long-term HD patients were significantly lower before (p<0.05) and immediately after 
(P<0.05) HD than that of short-term HD patients. We did not observe any significant 
differences in the GSH, GSSG, GSSG/GSH and Hb levels between the two groups prior to 
and after HD. No correlation was found between the HO-1 expression, the measured 
biochemical parameters, and the HD adequacy (Kt/V). 
To estimate the effects of HD on the different parameters, the ratios (after HD)/(before 
HD) of the measured metabolites and the HO-1 mRNA levels were correlated. Significant 
correlation were found between the change in HO-1 mRNA level and the changes in plasma 
Hb level (r=0.72, P<0.001) and plasma Bi level (r=0.71, P<0.002) (Fig. 12). We found no 
other significant relationship between the changes in the other measured oxidative stress 
markers. 
Fig. 12. Correlation of the FID-induced changes (ratio of values immediately after FID and before FID) 
in plasma hemoglobin (Fib) (r^0.72, P<0.001) and bilirubin (Bi) (r=0.71, P<0.002) levels with FIO-1 
mRNA 
4.5-3 
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The patients exhibited different levels of HO-1 inducibility, depending on the duration 
of their HD program. The short-term HD patients (n=7) had a higher baseline mRNA 
expression, which remained roughly the same during HD (Fig. 13A) and decreased slightly 
48 h after HD, but these changes were not significant. 
Fig. 13. HO-1 mRNA expression before, immediately after, and 48 h following HD in (A) short-term HD 
patients and (B) in long-term HD patients 
The long-term HD patients (rc=10) had a low baseline HO-1 mRNA expression, which 
underwent a one- to five-fold increase immediately after HD, but which had returned to the 
original value by 48 h (Fig. 13B). 
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4. DISCUSSION 
4.1. FISH analysis of the break point regions of the Costello syndrome 
patient 
In conclusion, we have confirmed the translocation breakpoint of the patient with 
Costello syndrome on chromosome lq25 and mapped it to a 109-kb region. The breakpoint on 
chromosome 22 was refined to q 13.1, and a cosmid with an insert of 38 kb was found that 
spanned the breakpoint. Suri and Garrett [58] described a Costello patient with acoustic 
neurinoma and cataract that are both features of neurofibromatosis type 2 (NF2). Although the 
authors did not find a deletion or point mutation of the NF2 gene, located in 22ql2.2, it has 
been suggested that the gene for Costello syndrome might be close to NF2. If the Costello 
gene is located in 22ql3.1, an inversion might have happened in the Costello/NF2 patient that 
escaped detection by conventional cytogenetic analysis. Further molecular analyses of the 
breakpoints on chromosomes 1 and 22 are necessary to show whether a single gene or more 
genes are affected by the translocation. Mutation screening in future studies of patients with 
Costello syndrome who have a normal karyotype will show whether any of the genes located 
near/at the breakpoints identified in our studies is the causative gene, or one of the causative 
genes for this syndrome. 
4.2. Choosing a method to measure HO-1 induction 
Quantitation of nucleic acids has become an essential tool in molecular diagnostics. 
Despite the fact that a number of methods are available for this purpose the procedures 
involved are rather cumbersome and each of them has its advantages and disadvantages. 
In hybridization methods like Northern blotting, the RNase protection assay and chip 
technology for detecting specific mRNAs, the reaction kinetics are easier to determine, but the 
sensitivity is not sufficient for most practical applications. In contrast, due to the amplifying 
effect, PCR-based methods are more sensitive. However, the kinetic of PCR is more complex 
and hence the use of PCR as a quantitative method is not straightforward. 
In the past few years, there have been many publications dealing with the quantitation 
of PCR products. The first approaches were only semiquantitative and were based on limiting 
dilution of the analyte [59]. Other methods used external standard curves for quantitation [60] 
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or low-stringency PCR [61]. None of these approaches overcame the problem of inhibition of 
individual probes. As a consequence, the next generation focused on amplification reactions 
that were internally controlled, either by co-amplification of internal endogenous standards, 
such as housekeeping genes [62, 63], or by introduction of an artificial exogenous competitor 
fragment [64-66]. For detailed reviews, see Clementi et al. [67,68]. 
Competitive PCR is a powerful tool for accurate quantification of low amount of DNA 
or RNA. It has several well established advantages over other methods for RNA quantitation 
utilizing RT-PCR [69-71], The procedure relies on the co- reverse transcription and 
amplification of the sequence of interest with a serially diluted synthetic RNA fragment of 
known concentration (competitor) using a single set of primers [72, 73]. In particular, being 
the quantification procedure based on the calculation of the ratio between the amounts of 
competitor and target products, the technique is unaffected by the overall yield of either the 
RT or PCR steps, allows the experimenter to reach the plateau of amplification, and is 
insensitive to the formation of aspecific products. 
The limiting step in the development of a competitive RT-PCR assay, however, is 
represented by the construction of competitor RNA templates. For this purpose we used a 
PCR based in vitro mutagenesis method [52], which does not require cloning of template 
DNA, and other labor intensive methods using restriction endonuclease and ligation 
techniques [74-77]. By using this method, since the competitor RNAs differ in size from the 
targets, the resulting amplification products can be simply resolved by gel electrophoresis and 
detected by ethidium bromide staining, avoiding the need for complex separation or internal 
hybridization procedures, in contrast to other competitive methods [78, 79]. 
The other problem using an externally created competitor is that although it is capable 
of absolute measurement, in real world usage it can be only applied when the amount of the 
analyzed sample is exactly known. This difficulty is usually overcome by using the RNA of a 
housekeeping gene as external control in other methods [62, 63], This approach has its own 
difficulties however. The PCR amplification of the two different primers, which amplifies the 
external control and the target sequence usually have different non-linear amplification 
characteristic. Furthermore in this duplex PCR the primer-primer formation, primer-template 
interaction may further complicate the measurements and requires non-linear calibration 
curves and complex software for the data analysis. To decrease the above mentioned effects 
the kinetics obtained during the exponential phase of PCR are used for quantification. For 
these measurements currently the real time PCR methods using fluorescent detection are 
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suitable as the conventional methods (staining with ethidium bromide and gel electrophoresis) 
are not sensitive enough. 
Overall, the competitive RT-PCR is an affordable robust technique which does not need 
special RNA purification and unaffected by the yield of either the RT or PCR steps. On the 
negative side, it is labor intensive and time consuming, thus limiting the numbers of samples 
which can be analyzed at a given time. LightCycler RT-PCR is costly and very susceptible to 
even traces of inhibitors, but it allows high-throughput processing of samples. 
Free heme is a substrate and inductor of its catabolizing enzyme, HO-1, which is also 
expressed in the lympho-, mono- and granulocytes in blood [80]. This let us set up a 
convenient methodology for our measurements on blood. HO-1 is transcriptionally induced 
and we could therefore apply a sensitive competitive RT-PCR method to measure the 
increased copy number of HMOX1 mRNA instead of measuring HO-1 protein by 
immunoassay. Compared to immunoassay methods RNA copy number based methods are 
more sensitive due to the amplifying chain reaction of PCR. The method was sensitive enough 
for the quantitative analysis of HMOX1 mRNA separated from 100 pi of whole blood. In our 
experiments the target tissue was blood therefore we could use the white blood cell count to 
quantify the samples and measure HMOX1 mRNA copy number per white blood cell. 
4.3. HO-1 expression in mature and premature neonates 
Heme functions as a double-edged sword. In moderate quantities and bound to protein, 
it forms an essential element for various biological processes, but when unleashed in large 
amounts, it can become toxic by mediating oxidative stress and inflammation. The effect of 
this free heme on the vascular system is determined by extracellular factors, such as 
hemoglobin/heme-binding proteins, haptoglobin, albumin, and hemopexin, and intracellular 
factors, including heme oxygenases and ferritin. Heme oxygenase enzyme activity results in 
the degradation of heme and the production of iron, carbon monoxide, and biliverdin. All 
these heme-degradation products are potentially toxic, but may also provide strong 
cytoprotection, depending on the generated amounts and the microenvironment. 
Approximately 5% of newborns suffer from neonatal jaundice, or hyperbilirubinemia. If the 
bilirubin levels become dangerously high, bilirubin passes through the blood-brain barrier and 
can cause neuronal damage associated with kemicterus [81]. The most common treatment for 
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hyperbilirubinemia is phototherapy, in which the jaundiced infant is exposed to blue light. 
The therapeutic effect is mediated by photoisomerization of unconjugated bilirubin, resulting 
in more polar and readily excretable photoisomers [82]. Recently, alternative treatment with 
competitive inhibitors of HO activity, such as stannic mesoporphyrin (single dose of 6 
pmol/kg), has shown to prevent and to reverse bilirubinemia [83, 84]. 
Under normal physiological conditions, most cells express low or undetectable levels of 
HO-1 protein [85]. In our study, the elevated HO-1 expression level immediately after birth is 
an indicator of oxidative stress in both mature and premature newborns. As the HO-1 levels 
increased during the following days (Fig. 10.) we can conclude that HO-1 is inducible in this 
early stage in both mature and premature neonates. The fact that the induction of HO-1 
mRNA and its maximum precede the maximal bilirubin levels (Fig. 11.) demonstrates that 
HO-1 is functional and cleaves free heme to biliverdin, CO and Fe2+. Due to the fact that 
neonates bellow 32 weeks of gestation have a very immature antioxidant enzymatic activity 
same oxidative stress can lead to a higher stress response. They are also more susceptible to 
oxidative injury caused by the oxidative stress. Therefore we think that the earlier up-
regulation of HO-1 expression of premature neonates could be perhaps attributed to the 
oxidative stress caused by the extra 0 2 administration in these patients. However we found no 
significant correlation between HO-1 expression and the Fi02 values in the examined patients. 
It could be because of the statistically low number of patients on extra 0 2 therapy and that 0 2 
was supplied only to reach 90% saturation thus the generated oxidative stress must had been 
quite modest in these patients compared to the oxidative effect of liberated free heme. By our 
data inducibility of HO-1 does not depend on the gestational age. 
It has been shown that in species in which hemolysis takes place post parturition, the 
activity of HO is enhanced in the early newborn period [86]. Our results in human newborns 
confirm this finding. It is also suggested that HO-1 activity is required for iron reutilization in 
mammals [35] for the prevention of abnormal iron accumulation in hepatic and renal cells, 
which otherwise contributes to oxidative damage, tissue injury and chronic inflammation. 
HMOX1-deficient adult mice developed an anemia associated with abnormally low serum 
iron levels, yet accumulated hepatic and renal iron that contributed to macromolecular 
oxidative damage, tissue injury, and chronic inflammation. These results indicate that 
HMOX1 has an important recycling role by facilitating the release of iron from hepatic and 
renal cells. Accordingly, our results underlines that the early inducibility of HO-1 even in 
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premature neonates is essential to avoid iron metabolic disorders and the injury caused by 
oxidative stress. 
The one HMOX1 deficient patient suffered from growth failure, anemia, tissue iron 
deposition, lymphadenopathy, leukocytosis, and increased sensitivity to oxidant injury. He 
ultimately succumbed to a premature death [87]. In an animal model of HO-1 deficiency, 
mice lacking the gene frequently die in utero, and those surviving to term display a phenotype 
similar to the HO-1-deficient boy [35]. Clearly, HO-1 is necessary to the survival of 
organisms. In our study both the mature and premature neonates we investigated were free 
from any organ manifestation of oxidative stress. In spite of the fact that many enzymes 
shows enzyme immaturity in premature neonates the two groups of patients did not exhibit 
differences in HO-1 expression pattern or inducibility. We therefore concluded that HO-1 
plays a crucial role in the early physiological adaptation of both mature and premature 
neonates. 
Oxygen radical injury is a common pathogenic mechanism in a number of neonatal 
diseases, including idiopathic respiratory distress syndrome, retinopathy of prematurity, 
bronchopulmonary dysplasia, subependymal and intraventricular hemorrhage and necrotizing 
enterocolitis [12, 88]. These disorders display a higher incidence in preterm infants with 
deficient antioxidant protective systems [89]. Our study indicates that premature neonates 
without any organ manifestation of oxygen radical injury are prepared to handle the released 
heme by the induction of the HO-1 system during neonatal adaptation. The question arises of 
whether the disturbance of HO-1 inducibility plays a role in premature newborns with 
"oxygen radical disease of prematurity". 
4.4. HO-1 expression in young hemodialysed uremic patients 
Oxidized free hemoglobin in the plasma mediates low-density lipoprotein oxidation and 
provides the endothelium with heme, which greatly enhances the oxidant-mediated cell injury, 
resulting in the endothelial dysfunction usually present in HD-treated uremic patients [35, 90]. 
Besides the oxidant insult of HD per se, a compromised erythrocyte defense mechanism 
against free oxygen radicals has been recognized to contribute to the HD-induced oxidative 
hemolysis in uremic patients [91, 92]. However, after heme-induced sensitization, the 
endothelium responds to chronic heme exposure by up regulating a group of stress proteins to 
maintain the structural and functional integrity of the cells [93]. Hb metabolism plays an 
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important role in HD mediated endothelial injury. The changes in Hb metabolism in uremic 
patients on HD could also contribute to the accelerated progression of atherosclerosis. 
In our study the increased levels of Hb in the plasma indicated a mechanical and 
oxidative hemolysis during HD (Table 4). The consecutive increase in Bi is a result of the 
functional HO eliminating free heme and protecting the arterial endothelium from oxidative 
stress. The catabolic cleavage of heme by HO-1 results in biliverdin, carbon monoxide, and 
Fe2+, which in turn up regulates the FOX system. The FOX activity in the HD patients 
(0.89±0.03 before HD) was significantly (P<0.01) higher than that in the controls 
(0.59±0.01), possibly as a result of the oxidative stress in the HD patients (Table 4). During 
HD, FOX activity increased significantly (0.89±0.03 before and 0.96±0.04 after HD, P<0.05) 
due to the oxidative stress caused by HD. 
In the HD patients, the ratio GSSG/GSH was higher than in controls, indicating that the 
oxidative stress in uremic HD patients. However, significant changes were not observed 
during HD, suggesting that the free heme was effectively catabolized by the HO. The rapid 
up-regulation of HO-1, and the consecutive up-regulation of the FOX system eliminates the 
free heme and stops the further generation of free radicals. 
The homocysteine concentration was significantly higher in the HD patients than 
controls. Such an increased homocysteine level is an independent risk factor for vascular 
disease, a sign of progressing atherosclerosis [94]. During HD, homocysteine was dialyzed 
out from the plasma, the level in the patients therefore decreased significantly. 
This study, which monitored the alteration in the HD-associated oxidative stress after 
one HD session, revealed significant differences in HO-1 inducibility, depending on the 
duration of HD treatment. In those patients who had been on HD for a shorter duration, the 
baseline HO-1 mRNA expression was higher than in those undergoing long-term HD. In the 
short-term patients, the plasma Hb level did not increase significantly during one HD session, 
because of the already elevated HO-1 level, and HO-1 was not further induced. In the long-
term HD patients, the baseline HO-1 mRNA expression was low and the HO-1 expression 
was up-regulated one- to five-fold during HD, due to the ensuing hemolysis. 
Our study measured the induction of the HO-1 mRNA level, which in turn leads to 
elevated HO-1 levels. However, HO-1 activity can be different before and after HD because 
of the clearance of toxic metabolites from the plasma by HD. These toxic metabolites may 
inhibit HO-1 activity, resulting in an impaired cytoprotective capacity prior to HD. 
As we observed a significant correlation between the changes in plasma Hb and HO-1 
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mRNA levels (/ ,<0.001) and also between the changes in plasma Bi and HO-1 mRNA levels 
(P<0.002), but not between the baseline HO-1 expression and the various measured 
biochemical parameters, we concluded that the HO-1 mRNA induction during HD is due to 
the hemolysis that occurs, but the baseline HO-1 expression is modulated by other factors. 
These results are in accordance with a study where the effect of erythropoietin treatment on 
hemolysis and HO-1 mRNA levels was investigated [95] in HD patients. A previous study 
demonstrated that endurance exercise in humans is also followed by an increased HO-1 
mRNA expression in the monocytes, leukocytes, and (less so) lymphocytes [80]. Our results 
relating to the HO-1 mRNA expression reveal differences in short- and long-term HD 
patients, very similar to those reported in that study. In untrained subjects at rest, the HO-1 
mRNA exhibited a higher baseline expression than in athletes [80]. It was suggested that the 
down-regulation of the baseline expression of HO-1 reflect an adaptation mechanism to 
regular exercise training. The corresponding change in our patients could be attributed to a 
mechanism of adaptation to the regularly occurring stress during HD. 
Experimental results suggested that a permanent up-regulation of HO-1 may afford 
protection against atherosclerosis, as HO-1 inhibits atherosclerotic lesion formation in low-
density lipoprotein receptor knockout mice [96]. It was also observed that cellular resistance 
to oxidative stress correlates positively with levels of HO-1 expression. In fact, researchers 
using various in vitro or in vivo stress paradigms have found that experimental up-regulation 
of HO-1 by treatment with heme or hemoglobin affords protection against subsequent 
oxidative challenges [97-99], Long-term HD patients are subject to a periodic (3 times a 
week) increase in free heme levels at the beginning of each HD sessions, as there is latency 
between the appearance of liberated heme and the transcriptional up-regulation of HO-1 
expression. This short (1-2 h) periodic exposure to increased free heme could cause the 
oxidative damage of endothelium and accelerate atherosclerosis. The chronic down-regulation 
of the baseline HO-1 expression in long-term HD patients may contribute to the progression 
of atherosclerosis. 
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5. SUMMARY 
We confirmed the translocation breakpoint of the patient with Costello syndrome on 
chromosome lq25 and mapped it to a 109-kb region. The breakpoint on chromosome 22 was 
refined to ql3.1, and a cosmid with an insert of 38 kb was found that spanned the breakpoint. 
We established a molecular genetic approach to measure directly the HMOX1 mRNA 
expression. This was convenient because: 
- HO-1 is transcriptionally regulated through the copy number of HMOX1 
mRNA 
- HO-1 is expressed in white blood cells thus sample collection was easy 
- the method was suitable to analyze even low amount (100 pi) of samples 
- the amount of mRNA could be expressed in reference with white blood cell 
count thus directly showing us mRNA copy number per cells 
- the method is robust and insensitive of inhibitors of either the RT or the PCR 
amplification steps 
- inexpensive, the whole procedure can be carried out with conventional non real 
time PCR instrument 
The drawback of the method was: 
- the competitor fragment was difficult to create 
- the procedure is labour-intensive 
In our experiments with HO-1 expression in healthy mature and premature we found 
that level of HO-1 expression and its induction profile are similar in both mature and 
premature neonates during the first week after birth. We also showed that HO-1 is functional 
in both mature and premature neonates because the induction of HO-1 was followed by the 
increase of the bilirubin levels. Thus in healthy neonates HO-1 does not play a role in the 
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transitory adaptation disturbances however it has an important role in the physiological 
adaptation process. Our study revealed the importance that further analysis is needed to 
analyze the HO-1 expression in neonates with organic manifestation of oxidative injury. 
In HD patients we showed that there is a significant difference in the HO-1 expression 
pattern between the patients depending on the duration of HD treatment. Short-term HD 
patients have an elevated HO-1 expression which may be contributed to an ongoing 
inflammation process. Long-term HD patients have a low base line HO-1 expression which 
was up regulated 1-5 fold during one single HD session. We also showed that the induction of 
HO-1 significantly correlated (P<0.001) with the occurring hemolysis and the liberated heme. 
We concluded that the periodical oxidative injury (three times a week) due to every HD 
sessions and the time delay between the occurring hemolysis and up-regulation of HO-1 could 
also contribute to the accelerated atherosclerosis rate in long-term HD patients. 
39 
6. ACKNOWLEDGEMENT 
I would like to thank Prof. Dr. Sándor Túri, Chairman of the Department of Pediatric, 
University of Szeged for the encouragement, scientific guidance and opportunity to work at 
the institute and Dr. Emőke Endreffy, the Head of the Genetic Laboratory of the Department 
of Pediatric, University of Szeged for her scientific guidance, and continuous support. I would 
also like to thank Dr. Ilona Németh and Dr. Eszter Karg, Department of Pediatric, University 
of Szeged for their scientific guidance and encouragement. 
I would also like to thank Dr. Márta Katona, Head of the PIC at the Department of 
Pediatric, University of Szeged and Dr. Hajnalka Orvos, Department of Gynecology, 
University of Szeged for the help and opportunity to collect samples from the neonate 
patients. I whish to acknowledge the practical help of Péter Ugocsai and Ildikó Farkas 
medical students in the laboratory experiments and sample collection. 
I would like to thank Prof. Andreas Gal, Chairman of the Institut fur Humangenetik, 
UKHE, Hamburg for his scientific guidance and the opportunity to work at the institute. I 
would also like to thank my supervisor Kerstin Kutsche, Ph.D. Institut fur Humangenetik 
UKHE, Hamburg for introducing me into the molecular genetics methods and for her help and 
scientific guidance in the Costello syndrome project. I would also like to thank to Margarita 
Stefanova and Barbara Schröder for their help in the FISH techniques and Kirsten von Hadeln 
and Karin Ziegler for cytogenetic analysis. 
The positional cloning studies were sponsored by Deutsche Forschungsgemeinschaft; 
Grant number: GRK336. The HO-1 expression studies were supported by OTKA grant 
022562, FKFP grant 0588/2000 and ETT grants 46406 and 46506/2000. 
40 
7. REFERENCES 
1. Costello JM. A new syndrome: mental subnormality and nasal papillomata. Aust 
Paediatr J 1977:13(2): 114-8. 
2. Costello JM. A new syndrome. NZ Med J 1971: 74: 397. 
3. Lurie IW. Genetics of the Costello syndrome. Am J Med Genet 1994: 52(3): 358-9. 
4. Berberich MS, Carey JC, Hall BD. Resolution of the perinatal and infantile failure to 
thrive in a new autosomal recessive syndrome with the phenotype of a storage disorder 
and furrowing of palmar creases. Proc. Greenwood Genet. Center 1991: 10: 78. 
5. Zampino G, Mastroiacovo P, Ricci R et al. Costello syndrome: further clinical 
delineation, natural history, genetic definition, and nosology. Am J Med Genet 1993: 
47(2): 176-83. 
6. Borochowitz Z, Pavone L, Mazor G et al. New multiple congenital anomalies: mental 
retardation syndrome (MCA/MR) with facio-cutaneous-skeletal involvement. Am J 
Med Genet 1992: 43(4): 678-85. 
7. Johnson JP, Golabi M, Norton ME et al. Costello syndrome: phenotype, natural 
history, differential diagnosis, and possible cause. J Pediatr 1998: 133(3): 441-8. 
8. Tartaglia M, Cotter PD, Zampino G et al. Exclusion of PTPN11 mutations in Costello 
syndrome: further evidence for distinct genetic etiologies for Noonan, cardio-facio-
cutaneous and Costello syndromes. Clin Genet 2003: 63(5): 423-6. 
9. Ion A, Tartaglia M, Song X et al. Absence of PTPN11 mutations in 28 cases of 
cardiofaciocutaneous (CFC) syndrome. Hum Genet 2002: 111(4-5): 421-7. 
10. Czeizel AE, Timar L. Hungarian case with Costello syndrome and translocation 
t(l,22). Am J Med Genet 1995: 57(3): 501-3. 
11. McCarthy K, Bhogal M, Nardi M et al. Pathogenic factors in bronchopulmonary 
dysplasia. Pediatr Res 1984: 18(5): 483-8. 
41 
12. Rogers S, Witz G, Anwar M et al. Antioxidant capacity and oxygen radical diseases in 
the preterm newborn. Arch Pediatr Adolesc Med 2000: 154(6): 544-8. 
13. Balla G, Vercellotti GM, Muller-Eberhard U et al. Exposure of endothelial cells to 
free heme potentiates damage mediated by granulocytes and toxic oxygen species. Lab 
Invest 1991: 64(5): 648-55. 
14. Jeney V, Balla J, Yachie A et al. Pro-oxidant and cytotoxic effects of circulating 
heme. Blood 2002:100(3): 879-87. 
15. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic 
renal disease. J Am Soc Nephrol 1998: 9(12 Suppl): S16-23. 
16. Rocco MV, Yan G, Gassman J et al. Comparison of causes of death using HEMO 
Study and HCFA end-stage renal disease death notification classification systems. The 
National Institutes of Health-funded Hemodialysis. Health Care Financing 
Administration. Am J Kidney Dis 2002: 39(1): 146-53. 
17. Rattazzi M, Puato M, Faggin E et al. New markers of accelerated atherosclerosis in 
end-stage renal disease. J Nephrol 2003:16(1): 11-20. 
18. Clermont G, Lecour S, Lahet J et al. Alteration in plasma antioxidant capacities in 
chronic renal failure and hemodialysis patients: a possible explanation for the 
increased cardiovascular risk in these patients. Cardiovasc Res 2000: 47(3): 618-23. 
19. Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for 
vascular disease. The European Concerted Action Project. Jama 1997: 277(22): 1775-
81. 
20. Durak I, Kacmaz M, Elgun S et al. Oxidative stress in patients with chronic renal 
failure: effects of hemodialysis. Med Princ Pract 2004: 13(2): 84-7. 
21. Loughrey CM, Young IS, Lightbody JH et al. Oxidative stress in haemodialysis. Qjm 
1994: 87(11): 679-83. 
22. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and 
clinical applications. Faseb J 1988: 2(10): 2557-68. 
42 
23. Stocker R, Yamamoto Y, McDonagh AF et al. Bilirubin is an antioxidant of possible 
physiological importance. Science 1987: 235(4792): 1043-6. 
24. Marilena G. New physiological importance of two classic residual products: carbon 
monoxide and bilirubin. Biochem Mol Med 1997: 61(2): 136-42. 
25. Tomaro ML, Batlle AM. Bilirubin: its role in cytoprotection against oxidative stress. 
Int J Biochem Cell Biol 2002: 34(3): 216-20. 
26. Baranano DE, Rao M, Ferris CD et al. Biliverdin reductase: a major physiologic 
cytoprotectant. Proc Natl Acad Sei U S A 2002: 99(25): 16093-8. 
27. Tyrrell RM, Basu-Modak S. Transient enhancement of heme oxygenase 1 mRNA 
accumulation: a marker of oxidative stress to eukaryotic cells. Methods Enzymol 
1994: 234: 224-35. 
28. Stocker R. Induction of haem oxygenase as a defence against oxidative stress. Free 
Radie Res Commun 1990: 9(2): 101-12. 
29. Nath KA, Haggard JJ, Croatt AJ et al. The indispensability of heme oxygenase-1 in 
protecting against acute heme protein-induced toxicity in vivo. Am J Pathol 2000: 
156(5): 1527-35. 
30. Wang LJ, Lee TS, Lee FY et al. Expression of heme oxygenase-1 in atherosclerotic 
lesions. Am J Pathol 1998:152(3): 711-20. 
31. Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced 
in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. 
Proc Natl Acad Sei U S A 1989: 86(1): 99-103. 
32. Kutty RK, Nagineni CN, Kutty G et al. Increased expression of heme oxygenase-1 in 
human retinal pigment epithelial cells by transforming growth factor-beta. J Cell 
Physiol 1994:159(2): 371-8. 
43 
33. Kutty RK, Kutty G, Rodriguez IR et al. Chromosomal localization of the human heme 
oxygenase genes: heme oxygenase-1 (HMOX1) maps to chromosome 22ql2 and 
heme oxygenase-2 (HMOX2) maps to chromosome 16pl3.3. Genomics 1994: 20(3): 
513-6. 
34. Seroussi E, Kedra D, Kost-Alimova M et al. TOM1 genes map to human chromosome 
22ql3.1 and mouse chromosome 8C1 and encode proteins similar to the endosomal 
proteins HGS and STAM. Genomics 1999: 57(3): 380-8. 
35. Poss KD, Tonegawa S. Heme oxygenase 1 is required for mammalian iron 
reutilization. Proc Natl Acad Sci U S A 1997: 94(20): 10919-24. 
36. Wagener FADTG, van Beurden HE, von den Hoff JW et al. The heme-heme 
oxygenase system: a molecular switch in wound healing. Blood 2002: 102: 521-528. 
37. Yachie A, Niida Y, Wada T et al. Oxidative stress causes enhanced endothelial cell 
injury in human heme oxygenase-1 deficiency. Journal of Clinical Invest 1999: 103: 
129-135. 
38. Ryter SW, Tyrrell RM. The heme synthesis and degradation pathways: role in oxidant 
sensitivity. Heme oxygenase has both pro- and antioxidant properties. Free Radic Biol 
Med 2000: 28(2): 289-309. 
39. Suttner DM, Dennery PA. Reversal of HO-1 related cytoprotection with increased 
expression is due to reactive iron. Faseb J 1999: 13(13): 1800-9. 
40. Lamb NJ, Quinlan GJ, Mumby S et al. Haem oxygenase shows pro-oxidant activity in 
microsomal and cellular systems: implications for the release of low-molecular-mass 
iron. Biochem J 1999: 344 Pt 1: 153-8. 
41. Dennery PA, Visner G, Weng YH et al. Resistance to hyperoxia with heme 
oxygenase-1 disruption: role of iron. Free Radic Biol Med 2003: 34(1): 124-33. 
44 
42. Abraham NG, Lavrovsky Y, Schwartzman ML et al. Transfection of the human heme 
oxygenase gene into rabbit coronary microvessel endothelial cells: protective effect 
against heme and hemoglobin toxicity. Proc Natl Acad Sei U S A 1995: 92(15): 6798-
802. 
43. Dennery PA, Sridhar KJ, Lee CS et al. Heme oxygenase-mediated resistance to 
oxygen toxicity in hamster fibroblasts. J Biol Chem 1997: 272(23): 14937-42. 
44. Rogers B, Yakopson V, Teng ZP et al. Heme oxygenase-2 knockout neurons are less 
vulnerable to hemoglobin toxicity. Free Radic Biol Med 2003: 35(8): 872-81. 
45. Yamada N, Yamaya M, Okinaga S et al. Microsatellite polymorphism in the heme 
oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J 
Hum Genet 2000: 66(1): 187-95. 
46. da Silva JL, Morishita T, Escalante B et al. Dual role of heme oxygenase in epithelial 
cell injury: contrasting effects of short-term and long-term exposure to oxidant stress. 
J Lab Clin Med 1996: 128(3): 290-6. 
47. Hebbel RP, Eaton JW. Pathobiology of heme interaction with the erythrocyte 
membrane. SeminHematol 1989: 26(2): 136-49. 
48. Burke DT, Carle GF, Olson MV. Cloning of large segments of exogenous DNA into 
yeast by means of artificial chromosome vectors. 1987. Biotechnology 1992: 24:172-
8. 
49. Philippsen P, Stotz A, Scherf C. DNA of Saccharomyces cerevisiae. Methods 
Enzymol 1991: 194: 169-82. 
50. Sambrook J, Fritsch E, Maniatis T. Molecular Cloning, in A Laboratory Manual. 
1989, Cold Spring Harbor Laboratory: New York. 
51. Kutsche K, Glauner E, Knauf S et al. Cloning and characterization of the breakpoint 
regions of a chromosome 11;18 translocation in a patient with hamartoma of the 
retinal pigment epithelium. Cytogenet Cell Genet 2000: 91(1-4): 141-7. 
45 
52. Waha A, Watzka M, Koch A et al. A rapid and sensitive protocol for competitive 
reverse transcriptase (cRT) PCR analysis of cellular genes. Brain Pathol 1998: 8(1): 
13-8. 
53. Jacobsen J, Wennberg RP. Determination of unbound bilirubin in the serum of 
newborns. Clin Chem 1974: 20(7): 783. 
54. Johnson DA, Osaki S, Frieden E. A micromethod for the determination of ferroxidase 
(ceruloplasmin) in human serums. Clin Chem 1967: 13(2): 142-50. 
55. Feussner A, Rolinski B, Weiss N et al. Determination of total homocysteine in human 
plasma by isocratic high-performance liquid chromatography. Eur J Clin Chem Clin 
Biochem 1997: 35(9): 687-91. 
56. Nemeth I, Boda D. Blood glutathione redox ratio as a parameter of oxidative stress in 
premature infants with IRDS. Free Radic Biol Med 1994:16(3): 347-53. 
57. Klaus MH, Fanaroff AA. Care of the High-Risk Neonate. 5 ed. Philadelphia: W.B. 
Saunders, 2001. 
58. Suri M, Garrett C. Costello syndrome with acoustic neuroma and cataract. Is the 
Costello locus linked to neurofibromatosis type 2 on 22q? Clin Dysmorphol 1998: 
7(2): 149-51. 
59. Simmonds P, McOmish F, Yap PL et al. Sequence variability in the 5' non-coding 
region of hepatitis C virus: identification of a new virus type and restrictions on 
sequence diversity. J Gen Virol 1993: 74 (Pt 4): 661-8. 
60. Whitby K, Garson J A. Optimisation and evaluation of a quantitative 
chemiluminescent polymerase chain reaction assay for hepatitis C virus RNA. J Virol 
Methods 1995: 51(1): 75-88. 
61. Caballero OL, Villa LL, Simpson AJ. Low stringency-PCR (LS-PCR) allows entirely 
internally standardized DNA quantitation. Nucleic Acids Res 1995: 23(1): 192-3. 
46 
62. Chelly J, Montarras D, Pinset C et al. Quantitative estimation of minor mRNAs by 
cDNA-polymerase chain reaction. Application to dystrophin mRNA in cultured 
myogenic and brain cells. Eur J Biochem 1990: 187(3): 691-8. 
63. Mallet F, Hebrard C, Livrozet JM et al. Quantitation of human immunodeficiency 
virus type 1 DNA by two PCR procedures coupled with enzyme-linked oligosorbent 
assay. J Clin Microbiol 1995: 33(12): 3201-8. 
64. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain 
reaction. Proc Natl Acad Sci U S A 1989: 86(24): 9717-21. 
65. Gilliland G, Perrin S, Blanchard K et al. Analysis of cytokine mRNA and DNA: 
detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad 
Sci U S A 1990: 87(7): 2725-9. 
66. Besnard NC, Andre PM. Automated quantitative determination of hepatitis C virus 
viremia by reverse transcription-PCR. J Clin Microbiol 1994: 32(8): 1887-93. 
67. Clementi M, Menzo S, Manzin A et al. Quantitative molecular methods in virology. 
Arch Virol 1995:140(9): 1523-39. 
68. Clementi M, Menzo S, Bagnarelli P et al. Quantitative PCR and RT-PCR in virology. 
PCR Methods Appl 1993: 2(3): 191-6. 
69. Nedelman J, Heagerty P, Lawrence C. Quantitative PCR with internal controls. 
Comput Appl Biosci 1992: 8(1): 65-70. 
70. Diviacco S, Norio P, Zentilin L et al. A novel procedure for quantitative polymerase 
chain reaction by coamplification of competitive templates. Gene 1992: 122(2): 313-
20. 
71. Siebert PD, Larrick JW. Competitive PCR. Nature 1992: 359(6395): 557-8. 
72. Siebert PD, Larrick JW. PCR MIMICS: competitive DNA fragments for use as 
internal standards in quantitative PCR. Biotechniques 1993: 14(2): 244-9. 
47 
73. Lion T, Izraeli S, Henn T et al. Monitoring of residual disease in chronic myelogenous 
leukemia by quantitative polymerase chain reaction. Leukemia 1992: 6(6): 495-9. 
74. Apostolakos MJ, Schuermann WH, Frampton MW et al. Measurement of gene 
expression by multiplex competitive polymerase chain reaction. Anal Biochem 1993: 
213(2): 277-84. 
75. Bolton MC, Dudhia J, Bayliss MT. Quantification of aggrecan and link-protein 
mRNA in human articular cartilage of different ages by competitive reverse 
transcriptase-PCR. Biochem J 1996: 319 (Pt 2): 489-98. 
76. Paschen W, Djuricic B. Regional differences in the extent of RNA editing of the 
glutamate receptor subunits GluR2 and GluR6 in rat brain. J Neurosci Methods 1995: 
56(1): 21-9. 
77. Wu J, Sullivan DE, Gerber MA. Quantitative polymerase chain reaction for hepatitis B 
virus DNA. J Virol Methods 1994:49(3): 331-41. 
78. Becker-Andre M, Hahlbrock K. Absolute mRNA quantification using the polymerase 
chain reaction (PCR). A novel approach by a PCR aided transcript titration assay 
(PATTY). Nucleic Acids Res 1989: 17(22): 9437-46. 
79. Henco K, Heibey M. Quantitative PCR: the determination of template copy numbers 
by temperature gradient gel electrophoresis (TGGE). Nucleic Acids Res 1990:18(22): 
6733-4. 
80. Niess AM, Passek F, Lorenz I et al. Expression of the antioxidant stress protein heme 
oxygenase-1 (HO-1) in human leukocytes. Free Radic Biol Med 1999: 26(1-2): 184-
92. 
81. Gourley GR. Bilirubin metabolism and kernicterus. Adv Pediatr 1997: 44: 173-229. 
82. McDonagh AF, Lightner DA. 'Like a shrivelled blood orange'-bilirubin, jaundice, and 
phototherapy. Pediatrics 1985: 75(3): 443-55. 
48 
83. Kappas A, Drummond GS, Valaes T. A single dose of Sn-mesoporphyrin prevents 
development of severe hyperbilirubinemia in glucose-6-phosphate dehydrogenase-
deficient newborns. Pediatrics 2001:108(1): 25-30. 
84. Kappas A, Drummond GS, Henschke C et al. Direct comparison of Sn-
mesoporphyrin, an inhibitor of bilirubin production, and phototherapy in controlling 
hyperbilirubinemia in term and near-term newborns. Pediatrics 1995: 95(4): 468-74. 
85. Wagener FA, Volk HD, Willis D et al. Different faces of the heme-heme oxygenase 
system in inflammation. Pharmacol Rev 2003: 55(3): 551-71. 
86. Maines MD, Kappas A. Metals as regulators of heme metabolism. Science 1977: 
198(4323): 1215-21. 
87. Yachie A, Niida Y, Wada T et al. Oxidative stress causes enhanced endothelial cell 
injury in human heme oxygenase-1 deficiency. J Clin Invest 1999:103(1): 129-35. 
88. Saugstad OD. Oxygen toxicity at birth: the pieces are put together. Pediatr Res 2003: 
54(6): 789. 
89. Sullivan JL. Iron, plasma antioxidants, and the 'oxygen radical disease of prematurity'. 
Am J Dis Child 1988:142(12): 1341-4. 
90. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002: 
105(9): 1135-43. 
91. Turi S, Nemeth I, Vargha I et al. Erythrocyte defense mechanisms against free oxygen 
radicals in haemodialysed uraemic children. Pediatr Nephrol 1991: 5(2): 179-83. 
92. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M et al. Glutathione antioxidant 
system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 
1996: 21(6): 845-53. 
93. Balla J, Balla G, Jeney V et al. Ferriporphyrins and endothelium: a 2-edged sword-
promotion of oxidation and induction of cytoprotectants. Blood 2000: 95(11): 3442-
50. 
49 
94. Yeun JY, Kaysen GA. C-reactive protein, oxidative stress, homocysteine, and troponin 
as inflammatory and metabolic predictors of atherosclerosis in ESRD. Curr Opin 
Nephrol Hypertens 2000: 9(6): 621-30. 
95. Calo LA, Stanic L, Davis PA et al. Effect of epoetin on HO-1 mRNA level and plasma 
antioxidants in hemodialysis patients. Int J Clin Pharmacol Ther 2003:41(5): 187-92. 
96. Ishikawa K, Sugawara D, Wang X et al. Heme oxygenase-1 inhibits atherosclerotic 
lesion formation in ldl-receptor knockout mice. Circ Res 2001: 88(5): 506-12. 
97. Balla J, Jacob HS, Balla G et al. Endothelial-cell heme uptake from heme proteins: 
induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci U 
S A 1993:90(20): 9285-9. 
98. Otterbein L, Sylvester SL, Choi AM. Hemoglobin provides protection against lethal 
endotoxemia in rats: the role of heme oxygenase-1. Am J Respir Cell Mol Biol 1995: 
13(5): 595-601. 
99. Nath KA, Balla G, Vercellotti GM et al. Induction of heme oxygenase is a rapid, 
protective response in rhabdomyolysis in the rat. J Clin Invest 1992: 90(1): 267-70. 
50 
8. APPENDIX 
